Reduced endoglin activity limits cardiac fibrosis and improves survival in heart failure.
about
Targeting BMP signalling in cardiovascular disease and anaemiaA Computational Study of the Factors Influencing the PVC-Triggering Ability of a Cluster of Early Afterdepolarization-Capable MyocytesL-Endoglin overexpression increases renal fibrosis after unilateral ureteral obstruction.Circulating fibrocytes and Crohn's disease.Endoglin haplo-insufficiency modifies the inflammatory response in irradiated mouse hearts without affecting structural and mircovascular changes.Biventricular remodeling in murine models of right ventricular pressure overloadReducing endoglin activity limits calcineurin and TRPC-6 expression and improves survival in a mouse model of right ventricular pressure overload.The role of TGFβ1 and LRG1 in cardiac remodelling and heart failure.MicroRNA-208a increases myocardial fibrosis via endoglin in volume overloading heart.Comparison of reendothelialization and neointimal formation with stents coated with antibodies against endoglin and CD34 in a porcine modelTargeting endoglin, an auxiliary transforming growth factor β coreceptor, to prevent fibrosis and heart failureThe TGF-β pathway mediates doxorubicin effects on cardiac endothelial cells.Endoglin: a critical mediator of cardiovascular healthCirculating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertensionThe pathogenesis of cardiac fibrosis.IL-1 induces proinflammatory leukocyte infiltration and regulates fibroblast phenotype in the infarcted myocardium.Endoglin for tumor imaging and targeted cancer therapy.Atrial fibrosis: a risk stratifier for atrial fibrillation.Biomarkers in mechanical circulatory support.The role of endoglin in kidney fibrosis.Conditional knockout of activin like kinase-1 (ALK-1) leads to heart failure without maladaptive remodeling.The microRNA-15 family inhibits the TGFβ-pathway in the heart.Suppressive effect of epigallocatechin-3-O-gallate on endoglin molecular regulation in myocardial fibrosis in vitro and in vivoTransforming growth factor β: A potential biomarker and therapeutic target of ventricular remodeling.The Role of Endoglin in Myocardial FibrosisCardiosphere-Derived Cells Require Endoglin for Paracrine-Mediated Angiogenesis.Endoglin selectively modulates transient receptor potential channel expression in left and right heart failure.Oxidative stress, fibrosis, and early afterdepolarization-mediated cardiac arrhythmias.Valsartan regulates TGF-β/Smads and TGF-β/p38 pathways through lncRNA CHRF to improve doxorubicin-induced heart failure.Reduced activin receptor-like kinase 1 activity promotes cardiac fibrosis in heart failure.High soluble endoglin levels do not induce changes in structural parameters of mouse heart.Intra-Amniotic Soluble Endoglin Impairs Lung Development in Neonatal Rats.Anti-VEGF therapy reduces intestinal inflammation in Endoglin heterozygous mice subjected to experimental colitis.Bone Morphogenetic Protein 9 Reduces Cardiac Fibrosis and Improves Cardiac Function in Heart Failure.Pathophysiological Mapping of Experimental Heart Failure: Left and Right Ventricular Remodeling in Transverse Aortic Constriction Is Temporally, Kinetically and Structurally Distinct.Prognostication in Different Heart Failure Phenotypes: The Role of Circulating Biomarkers.
P2860
Q26783734-2B6B1F34-5EE3-4E21-9011-CDA22D0180A2Q27334990-77C2A129-36B5-47B9-968E-14250750D5E7Q34338572-91B7D1ED-D242-4643-A4FC-2F89F5A2D325Q34387011-043D7BE6-4CA6-480C-9AC7-AD50EE2159E0Q34873610-67AC1B5A-6D5D-4C7D-BA68-1F59775BFB2BQ34923598-7A25887A-AAE1-4177-ACDA-525453FA3D99Q35026300-2EBD0072-1556-4C09-9FCA-A40AA26B5B69Q35065245-62F0B96C-AE58-4398-A140-71E73825FA7CQ35083325-07D29674-B95B-459A-8B6B-01E65295432BQ35535453-B10C2DF5-00BE-4049-9D01-1031D19E62D3Q36106240-F6A9801F-9D0D-44B2-94D6-06CCB4EC9576Q36479962-D160E4B3-5F2A-4F02-8609-42944AD5DE98Q36825271-E3CA705D-F7BF-4ADB-A509-ECF5C00DAFB8Q37133815-D7BCB5C6-3BE4-403A-9D19-946CF095EF7FQ37161329-5E614F67-3332-4CAE-BBD9-B63B23D07253Q37293969-958A0242-F98B-41FE-A105-77CB6A73B1DCQ38074721-4EF63528-377C-4FA1-8B2B-DC725B70680AQ38081151-753105E5-393B-4E26-BDF1-27D99F2A9180Q38249997-787EA74E-0420-4876-86B0-3CB3492F64F3Q38273688-377950BB-069A-4BB8-9849-0881217194A8Q38755905-BB2A4705-CF01-4C1F-B571-4B02032E5D8BQ40036351-0EA80285-3D24-46C9-9EC7-1315B9AC6CA9Q41592964-CF88D0E9-3D43-4C0F-A4D7-DFF1921B7406Q41593391-B20F1193-8B49-4310-B302-DD59B4C36756Q41669775-AAA56798-7B2E-4201-9231-662AC12D117AQ42278077-F3C706C7-3C19-4CE9-A52F-12F39251E0CBQ42737239-FE59216F-C143-4685-BC92-D330A16CA1F3Q43246929-F4487329-B72B-4EC2-97F6-19F890A1E012Q47417752-4523A783-6B42-489A-BADE-7378F92620D9Q47779611-39DE8E09-2CE9-43BD-B4B5-CD53488EA53FQ47802388-D9302046-94FF-4FEF-AA96-1598BC11BA38Q47869716-E65FB5F6-5A52-4E02-BE85-541F25555B60Q50689698-896995D9-6FF4-4744-A049-1E51FB2D36C6Q52682504-1F2048EF-2B71-483E-8A9A-A78993734457Q54968385-4393AED0-EE0C-42EF-9A1C-6779EE37C095Q55343200-7ACB1786-36C8-4D23-AD8F-8B94ED78F0E3
P2860
Reduced endoglin activity limits cardiac fibrosis and improves survival in heart failure.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Reduced endoglin activity limits cardiac fibrosis and improves survival in heart failure.
@ast
Reduced endoglin activity limits cardiac fibrosis and improves survival in heart failure.
@en
type
label
Reduced endoglin activity limits cardiac fibrosis and improves survival in heart failure.
@ast
Reduced endoglin activity limits cardiac fibrosis and improves survival in heart failure.
@en
prefLabel
Reduced endoglin activity limits cardiac fibrosis and improves survival in heart failure.
@ast
Reduced endoglin activity limits cardiac fibrosis and improves survival in heart failure.
@en
P2093
P2860
P1433
P1476
Reduced endoglin activity limits cardiac fibrosis and improves survival in heart failure.
@en
P2093
Adil A Yunis
Corey Baker
David A Kass
Emily Mackey
Mark J Aronovitz
Michael E Mendelsohn
Michelle Letarte
Navin K Kapur
Richard H Karas
S Ananth Karumanchi
P2860
P304
P356
10.1161/CIRCULATIONAHA.111.080002
P407
P577
2012-05-16T00:00:00Z